After reading the article, my concern is that the article seems focus on Cellvizio and it's effectiveness for oral cancer treatment. I thought this was one area Convivo was on it's own so to speak. In the article, it is just listed as another device in the market, but the analysis by the authors is primarily on Cellvizio it seems to me.
However, once the results of the study in Melbourne are published, you'd have to assume this will create some comparisons of effectiveness.
Just surprised the Manua Kea product is seen as the leader in this area.
Maintain the rage, page-3
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OIL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $171.2M | |||
| Open | High | Low | Value | Volume |
| 20.5¢ | 20.5¢ | 20.0¢ | $15.10K | 75.16K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 292 | 20.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.0¢ | 16440 | 2 |
View Market Depth
| Last trade - 16.10pm 15/08/2024 (20 minute delay) ? |
| OIL (ASX) Chart |